Evotec AG Hits New 52-Week High at $26.20 (EVTC)
Evotec AG (NASDAQ:EVTC) set a new 52-week high during trading hours on Thursday, Analyst Ratings.Net reports. The company traded as high as $26.20 and last traded at $25.99, with a volume of 755,250 shares. The stock had previously closed at $26.03.
Separately, analysts at Stifel Nicolaus initiated coverage on shares of Evotec AG in a research note to investors on Tuesday, December 24th. They set a “buy” rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Evotec AG currently has a consensus rating of “Buy” and a consensus price target of $27.00.
Evotec AG has a 52-week low of $19.11 and a 52-week high of $26.07. The stock has a 50-day moving average of $23.98 and a 200-day moving average of $23.43. The company has a market cap of $2.156 billion and a P/E ratio of 69.60.
Evotec AG (NASDAQ:EVTC) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.36 earnings per share (EPS) for the quarter. The company had revenue of $87.40 million for the quarter, compared to the consensus estimate of $83.80 million.
Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.